ScholarIQanswers from OpenAlex & ORCID
Katja Rohwedder
ResearcherPublications, citations & collaboration network
Katja Rohwedder is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Katja Rohwedder have?
ScholarIQindexed works
Katja Rohwedder has 132 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Katja Rohwedder have?
ScholarIQcitation count
Katja Rohwedder has 2,060 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Katja Rohwedder?
ScholarIQh-index
Katja Rohwedder has an h-index of 16 in OpenAlex.
What is the i10-index of Katja Rohwedder?
ScholarIQi10-index
Katja Rohwedder has an i10-index of 28 in OpenAlex.
What is the OpenAlex record for Katja Rohwedder?
ScholarIQopenalex
The OpenAlex for Katja Rohwedder is on the source record.
What are the most-cited papers on Katja Rohwedder?
ScholarIQmost cited works
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin
Michael A. Nauck, Stefano Del Prato, Juris J. Meier, S. Durán‐García, Katja Rohwedder, M. Elze, Shamik Parikh
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
John Wilding, Vincent Woo, Katja Rohwedder, Jennifer Sugg, Shamik Parikh, for the Dapagliflozin 006 Study Group
Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data
Stefano Del Prato, Michael A. Nauck, S. Durán‐García, Laura Maffei, Katja Rohwedder, A. Theuerkauf, Shamik Parikh
Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial
S. Matthäei, Keith Bowering, Katja Rohwedder, A Grohl, Shamik Parikh, for the Study 05 Group
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin
Michael A. Nauck, Stefano Del Prato, S. Durán‐García, Katja Rohwedder, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh